A Stepwise Prostate Screen Found More Aggressive Cancers While Adding Few Harmless Diagnoses

CATEGORY: MEN’S HEALTH

Can screening catch the prostate cancers that matter without piling up diagnoses of tumors that never would have caused trouble? Finnish researchers built a three-step process to find out, and the first round of their trial, called ProScreen, shows the filter doing its job. Among men invited to screening, 11.3 aggressive cancers were detected per 1,000, compared with 6.2 per 1,000 among men left to usual care.¹ The downside stayed small. Roughly one extra low-grade, likely harmless cancer was diagnosed for every 900 men invited.

A Blood Test, Then a Second, Then a Scan

The trial covered 60,745 men aged 50 to 63 in Helsinki and Tampere. A lottery decided which one in four of them got an invitation, and that random sorting is what makes the two groups honestly comparable. Of the 15,201 men invited, about half took part. Screening then ran as a series of sieves. First came the familiar PSA test, which measures a protein the prostate releases into the blood. Men above the usual cutoff gave a second sample for a four-protein panel that estimates the odds of an aggressive tumor. Only men flagged by the panel went on to an MRI, and only suspicious scans led to needle sampling of the prostate. The cutoffs were concrete. A PSA of 3 or higher sent a man to the panel, and a panel risk score of 7.5% or higher sent him to the scanner. Each pass let more of the harmless cases fall out before anyone reached a biopsy table.

More of the Dangerous Kind, Barely More of the Harmless Kind

Among invited men, screening turned up 172 high-grade cancers, meaning tumors whose cells look aggressive under the microscope. That works out to 11.3 per 1,000 men. In the 45,544-man comparison group, ordinary medical care found 6.2 per 1,000 across roughly three years of records. Low-grade cancers, the slow kind that can sit quietly for decades, were diagnosed in 2.6 per 1,000 invited men versus 1.4 per 1,000 controls. The researchers put it plainly: one additional aggressive cancer came to light for every 196 men invited, against one additional harmless-looking diagnosis for every 909.¹ Avoiding that second kind of finding was the design’s whole purpose, because needless diagnoses, and the surgeries and anxiety that follow them, are the harm that has dogged PSA-only screening for decades. One more thing to keep straight when reading the figures: they average across everyone who received a letter, whether or not he showed up. That’s deliberate. A public program can only ever invite, so the honest measure of one is what the invitation itself accomplishes.

Found Early Is Not Yet Lives Saved

The real verdict on any cancer screen is whether fewer people die of the disease, and that answer sits a decade away; ProScreen will track these men for 10 to 15 years. Detecting more aggressive tumors early is the necessary first step, not the finish line. A flagged result along the way is also not a diagnosis. A high PSA often traces to an enlarged prostate or an infection, and most men who entered this pipeline walked out of it without cancer. What we have now is a first-round accounting of what a smarter sequence finds, with the comparison group’s cancers counted from about three years of national health records. Screening in the trial continues, and later rounds will show whether the early pattern holds. Whether it saves lives is the question the next decade answers.

Key Takeaways

• Invited men had 11.3 aggressive prostate cancers detected per 1,000 versus 6.2 per 1,000 with usual care, while harmless-looking diagnoses rose only from 1.4 to 2.6 per 1,000.
• The sequence of PSA test, four-protein blood panel, and MRI exists to keep men with slow, harmless tumors away from biopsies they don’t need.
• About half of invited men chose to participate, so these figures describe what an invitation achieves, not perfect attendance.
• Whether this approach lowers prostate cancer deaths won’t be known until follow-up runs its 10-to-15-year course.

References

1. Auvinen A, Tammela TLJ, Mirtti T, et al. Prostate Cancer Screening with PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial. JAMA. 2024;331(17):1452-1459. link